Sign in to fuzzto save your conversations, follow your research and come back anytime.
Jubilant Ingrevia
SectorChemicals
Jubilant Ingrevia Limited is a global integrated Life Science products and Innovative Solutions provider. Incorporated in 2019, the company serves Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers. It operates through three core segments: Speciality Chemicals, Nutrition and Health Solutions, and Life Science Chemicals. The company manufactures and supplies speciality intermediates, nutrition & health solutions, and life science chemicals through five facilities in India. Jubilant Ingrevia is the global largest producer of Niacinamide and among the top two manufacturers of Vitamin B3 globally. It serves over 1400 customers in more than 60 countries and offers custom research and manufacturing services. The company is part of the Jubilant Bhartia Group and became a separate entity following a demerger from Jubilant Pharmova Limited in 2021.
In the news
Jubilant Ingrevia board approves ₹189.2 crore Zettaone acquisition
Jubilant Ingrevia Q1 profit surges 41% to ₹106 crore, mixed analyst views
Marksans Pharma surges 13% on 64% Q4 PAT jump to ₹148 cr
Jubilant Ingrevia starts Gujarat plant dispatches under CDMO
Prabhudas Lilladher holds Jubilant Ingrevia at Rs 657 target
Jubilant Ingrevia Q3 profit drops 32% to ₹47 cr, declares ₹2.50 dividend
Company insights, generated from the most recent coverage.
Fine chemicals growth is concentrated in pyridine and diketene derivative chains — the same capacity that drove the Q1 beat, so a capacity bottleneck or price normalisation in those two chains would hit the whole upside case.
Up 5.15% to ₹672 on just 2.57 lakh shares — a low-volume drift higher, so this is continuation buying on lagged Q1 re-rating rather than fresh institutional accumulation.
CDMO pharma pipeline tripled after US and Europe roadshows, plus agro CDMO innovator volumes rolling out — this is the highest-visibility part of the story and the main reason the stock deserves a premium to legacy intermediates.